KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Invested Capital (2016 - 2025)

Charles River Laboratories International has reported Invested Capital over the past 17 years, most recently at $3.2 billion for Q4 2025.

  • Quarterly results put Invested Capital at $3.2 billion for Q4 2025, down 8.42% from a year ago — trailing twelve months through Dec 2025 was $3.2 billion (down 8.42% YoY), and the annual figure for FY2025 was $3.2 billion, down 8.42%.
  • Invested Capital for Q4 2025 was $3.2 billion at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
  • Over the last five years, Invested Capital for CRL hit a ceiling of $3.8 billion in Q3 2024 and a floor of $2.2 billion in Q1 2021.
  • Median Invested Capital over the past 5 years was $3.2 billion (2025), compared with a mean of $3.1 billion.
  • Biggest five-year swings in Invested Capital: rose 28.64% in 2021 and later dropped 12.23% in 2025.
  • Charles River Laboratories International's Invested Capital stood at $2.5 billion in 2021, then grew by 17.28% to $3.0 billion in 2022, then grew by 20.84% to $3.6 billion in 2023, then decreased by 3.91% to $3.5 billion in 2024, then fell by 8.42% to $3.2 billion in 2025.
  • The last three reported values for Invested Capital were $3.2 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.4 billion (Q2 2025) per Business Quant data.